Revenio Group 

$25
19
+$3+13.64% Friday 21:00

Statistics

Day High
25
Day Low
25
52W High
31.47
52W Low
25
Volume
200
Avg. Volume
-
Mkt Cap
0
P/E Ratio
32.05
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Apr 25
$0.45
Apr 24
$0.41
Apr 23
$0.39
Apr 22
$0.37
Mar 21
$0.38
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

6AugExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
0.16
0.21
0.26
0.31
Expected EPS
0.20171528832
Actual EPS
N/A

Financials

17.82%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
111.01MRevenue
19.79MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow REVXF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Sensors that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used by veterinarians, ophthalmologists and other personnel to measure intraocular pressure in animal patients. It also provides imaging devices comprising iCare EIDON, a device with confocal retinal imaging; iCare DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. In addition, the company offers iCare ILLUME, a screening software that helps to detect the early signs of diabetic retinopathy, age-related macular degeneration, and glaucoma using artificial intelligence; iCare CLINIC cloud software to store long-term IOP data; and Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.
Show more...
CEO
Mr. Jouni Toijala B.Sc., M.B.A.
Country
Finland
ISIN
FI0009010912

Listings

0 Comments

Share your thoughts

FAQ

What is Revenio Group stock price today?
The current price of REVXF is $25 USD — it has increased by +13.64% in the past 24 hours. Watch Revenio Group stock price performance more closely on the chart.
What is Revenio Group stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Revenio Group stocks are traded under the ticker REVXF.
Is Revenio Group stock price growing?
REVXF stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Revenio Group has showed a -10.23% decrease.
When is the next Revenio Group earnings date?
Revenio Group is going to release the next earnings report on August 06, 2026.
What were Revenio Group earnings last quarter?
REVXF earnings for the last quarter are 0.18 USD per share, whereas the estimation was 0.19 USD resulting in a -5.96% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Revenio Group revenue for the last year?
Revenio Group revenue for the last year amounts to 111.01M USD.
What is Revenio Group net income for the last year?
REVXF net income for the last year is 19.79M USD.
Does Revenio Group pay dividends?
Yes, REVXF dividends are paid annual. The last dividend per share was 0.45 USD. As of today, Dividend Yield (FWD)% is 0%.
In which sector is Revenio Group located?
Revenio Group operates in the Other sector.
When did Revenio Group complete a stock split?
The last stock split for Revenio Group was on March 20, 2020 with a ratio of 2:1.
Where is Revenio Group headquartered?
Revenio Group is headquartered in Vantaa, Finland.